Efficacy and Safety of GP40081 Сompared to NovoMix® 30 FlexPen® in Type 2 Diabetes Mellitus Patients
A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 264 participants.
Also called NCT04226105
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 264 participants
- Sponsor
- Registry
-
NCT04226105
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Russia
- Registry status
- Unknown status
Technical summary
Registry record NCT04226105. Randomized; no masking; primary purpose treatment. Start 2020-01-20 (actual); primary completion 2020-09-30 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of GP40081 Сompared to NovoMix® 30 FlexPen® in Type 2 Diabetes Mellitus Patients
- Condition
- Diabetes Mellitus, Type 2
- Condition
- Diabetes Mellitus
- Intervention (Drug)
- GP40081
- Intervention (Drug)
- NovoMix 30
- Lead sponsor
- Geropharm
Record details
- Record id
cardio:ct-nct04226105- Content hash
21b820952b6dc3c31b9c26cdb3a6a32cb53e2e15bbddb25533938903b0feb23c